Introduction
Covalentp osttranslational modifications on the unstructured N-terminal histonet ails play an important role in regulating the activity of human genes. [1] These modifications are introduced by 'writers' and, among others, include methylation, acetylation, phosphorylation,c itrullination, and ubiquitination. [2] Methylation is one of the most abundant and well-studied modifications on histones. [3] The transfer of am ethyl group from co-substrate S-adenosylmethionine (SAM) to lysine residues is catalyzed by histonel ysine methyltransferases (KMTs). [4] KMTsc an catalyze the addition of up to three methyl groups to the e-aminog roup of lysine residues, affording methyllysine (Kme), dimethyllysine (Kme2)a nd trimethyllysine (Kme3). [5] With the exception of DOT1L, an H3K79 methyltransferase, all KMTsc ontain ah ighlyc onserved SET (Su(var)3-9, enchanter-ofzeste, thritorax) domain, which is responsible for their catalytic activity. [6] SET domain containing lysine methyltransferase 7( SETD7, also knowna sS ET7/9) was originally identified as am onomethylase of lysine 4o nh istone 3( H3K4). [7] Unlike many other methyltransferases, SETD7 only monomethylates H3K4, but does not catalyze di-or trimethylation of lysine. This methylation mark (H3K4me) has af unctional effect on the chromatin state resulting in activation of transcription. SETD7 has also been found to catalyze methylation of ar ange of non-histone proteins,i ncludinge strogenr eceptor a (ERa), [8] DNA methyltransferases 1( DNMT1), [9] TAF10, [10] FoxO3, [11] transcription factors YY1 and Pdx1, [12] androgen receptor, [13] ARTD1, [14] b-catenin, [15] and tumor suppressor p53. [16] Recent biomedical studies revealed that SETD7 is involved in multiple signaling pathways, and its aberrant activity has been linked to various types of cancer [17] and vascular dysfunction in patients with type 2d iabetes. [18] The development of SETD7 small molecule inhibitors as chemical probesf or studying their biological activity in cells is therefore highly desired and may lead to the development of therapeutica gents for the treatment of human diseases. [18, 19] To date, only af ew selective SETD7 inhibitors have been identified. Clinicallya pproved antihistaminic cyproheptadine was found to inhibitS ETD7-mediatedm ethylation of H3K4 (IC 50 of 3.4 mm). The substrate in this study was ERa,a nd in vivo inhibition led to blocking of estrogen-dependent breast cancer cell growth in MCF7 cells. [20] As tructure-activity relationship study was performed, however,none of the analogues provedt ob em ore potent than cyproheptadine. [21] Several SAM derivatives have also been reported to inhibit SETD7 methyltransferase activity;f or instance, DAAM-3( IC 50 10 mm) [22] and DC-S239 (IC 50 4.59 mm). [23] Unfortunately,S AM-competitive inhibitors usually have poor selectivity amongsto ther methyltransferases due to the highly conserved SAM binding domain in the methyltransferase family.T he most potent known SETD7 inhibitor (IC 50 = 2.0 AE 0.2 nm)i s( R)-PFI-2 (Figure 1b-c) , whilei ts enantiomer (S)-PFI-2 proved to be av ery weak SETD7 inhibitor, highlighting that the stereochemistry of the amino acid side chain defines its potency. [24] (R)-PFI-2 is ah istone competitive inhibitor,a nd exhibitsa ni nhibition potencyi nv itro and in cellular assays. [24] Comparatives tudies demonstrated that (R)-PFI-2 is selectivef or SETD7 over 18 other human methyltransferases. SETD7 is ah istoneH 3K4 lysine methyltransferase involved in human gene regulation. Aberrant expression of SETD7 has been associated with variousd iseases, including cancer.T herefore, SETD7 is considered ag ood target for the development of new epigenetic drugs. To date, few selectives mall-molecule inhibitors have been reported that target SETD7, the most potent being (R)-PFI-2.H erein we report structure-activity relationship studies on (R)-PFI-2 and its analogues.Alibrary of 29 structuralanalogueso f(R)-PFI-2 was synthesized and evaluated for inhibition of recombinantly expressed human SETD7. The key interactions were found to be as alt bridge and ah ydrogen bond formed between (R)-PFI-2'sN H 2 + group and SETD7's Asp256 andH is252 residue, respectively.
Although the structure of (R)-PFI-2 in complex with SETD7 has been solved (Figure 1b) , no further analogues have been reported. To investigate which structural elements of (R)-PFI-2 are essential for effective inhibition of SETD7, we carried out a structure-activity relationship (SAR) study.W em odifiedt hree distinctive moieties that have apotential to crucially contribute to the potencyo f( R)-PFI-2:1 )The amino acid side chain (Figure 
Results and Discussion
We initiated our investigationsw ith the synthesis of (R)-PFI-2 (1)a nd its 29 structural analogues (Scheme 1). In general,t he synthesis was adapted from ap ublished protocol, [24] and starts from an unnatural d-amino acid;t ypicallyB oc-protected dphenylalanine derivatives were coupledt ot he requisite amines using EDCI, HOBt, and DIPEA. Then the Boc group was removedw ith TFAi nC H 2 Cl 2 ,f ollowed by ab asic workup to afford the free amine. The sulfonyl part of the inhibitor was synthesized from variousa ryl bromides (Scheme 1). These aryl bromidesw ere first reacted with benzyl mercaptan in the presence of Pd 2 (dba) 3 andX antphost oa fford aryl benzyl sulfides, followed by oxidation with trichloroisocyanuric acid to yield the corresponding sulfonyl chlorides. The sulfonyl chlorides were then coupled to the free amines in the presence of triethylamine in CH 2 Cl 2 to afford the desired structural analogues of (R)-PFI-2.
Initially,a ll synthesized compounds were tested for their inhibitory activity using an established matrix-assisted laser desorption-ionization time-of-flight mass spectrometry (MALDI-TOF MS) assay,m onitoring the monomethylation of as ynthetic 21-mer histone3 peptidem imic containing al ysine at position 4.
[25] In at ypical assay,2 00 nm of SETD7,1 0mm of H3K4 histonep eptide, 16 mm of SAM and 10 or 100 mm of compounds 1-30 were incubated for 1hour at 37 8C. For compounds showing > 50 %i nhibition at 100 mm,I C 50 values were determined. In cases where < 50 %i nhibition at 100 mm was observed, IC 50 values were not determined and this data is presenteda sI C 50 > 100 mm.E nzymatic activity of these compounds at 100 mm concentration can be found in Figure S1 in the Supporting Information (SI). Representative MALDI data of selected compounds at 10 mm are shown in Figure 2 . In ac ontrol experiment withouti nhibitor (5 %( v/v)o fD MSO) nearly quantitative methylation was observed in the presence of human SETD7 (m/z = 2269.5) (Figure 2a ). Under standard conditions, but in the presence of 10 mm of (R)-PFI-2 (compound 1), no methylation was observed in the MALDIs pectrum (Figure 2b) .
We furthere xamined the potency of (R)-PFI-2 against recombinantly expressed humanS ETD7.U nder our assay conditions, an IC 50 value of 138 nm waso btained for (R)-PFI-2 ( Figure 3 , compound 1), indicating very effective inhibition of SETD7 methyltransferase activity.P reviously reported IC 50 values for (R)-PFI-2 were 2.0 and 55 nm,r espectively; [24, 25b] the observed difference with our measured IC 50 value is due to differencesi n employed assay anda ssay conditions. Representative inhibition curvesc an be found in SI Figure S2 .T wo isomerso f1, with ortho-( compound 2)a nd para-CF 3 (compound 3)s ubstituentsa lso displayed excellent inhibitory activity with IC 50 valueso f2 03 and1 73 nm,r espectively.T he potencies of ana- logues 4-6 bearing am ethyl, chloro, or bromo functionality at the meta-position were evaluated next. All compounds were found to be excellent inhibitors of SETD7 with IC 50 values ranging from 132 to 178 nm.A lso compound 7,w hich does not contain any substituent on the phenyl ring, was found to be a good SETD7 inhibitor with an IC 50 of 266 nm.A ddinga ne xtra fused ring, as in the naphthalene-containingc ompound 8, gave an IC 50 of 145 nm,i ndicating that there is sufficient space availablef or additional functionalization. Notably,r emoving the entires ide chain (as in glycine-based compound 9)l ed to rather poor inhibition with an IC 50 of 79 mm,i mplying that the aromaticr ing is crucial for potency.
Next, the effect of modificationsi nt he pyrrolidine amide side chain was investigated ( Figure 1c ,p art B). Thea nalysiso f the crystal structure of (R)-PFI-2 as co-crystal with SETD7 and SAM (PDB ID:4 JLG) illustrates that the pyrrolidine part of the inhibitori sp ositioned insidet he lysine channelp ointingt owards SAM (Figure 1b ). Based on this structurali nformation,i t is clear that space in this pocket is limited and that as ignificant increasei nt he size of the pyrrolidine moiety would presumably not be tolerated. Indeed, 1-adamantyl-substituted compound 10 did not show any inhibitory activity against SETD7. No significant difference in IC 50 was observed when the five-membered ring of the pyrrolidine amide (compound 7, 266 nm)w as replaced by af our-membered ring:a nI C 50 of 290 nm was obtained for azetidine derived analogue 11.B y slightly increasing the ring size to piperidine or morpholine amide, asi na nalogues 12 and 13,I C 50 values of 1.3 and 1.9 mm were observed, respectively.T his result shows that a slight increase in ring size from five-to six-membered already leads to an approximate fivefold decrease in potency (compound 7 versus 12). Replacement of the five-membered ring with acyclicd iethylamine derivative 14 resulted in ah igher degree of rotational freedom,w hich could lead to as teric clash with SETD7'spocket;this proposition is in line with asurprisingly higherI C 50 value of 20 mm.A na lmost1 0-fold lower IC 50 of 2.6 mm was obtained by decreasing the size and rotational freedom in dimethylamine derivative 15.R emoval of the entire pyrrolidine amide side chain (as in compound 16), resulted in the formationo fa na chiral compound. This significant structural changec aused that 16 is no longer an inhibitor of SETD7 within limits of detection.
Finally,t he importance of the tetrahydroisoquinoline rings was investigated ( Figure 1c ,p art C). The simplest analogues 17-19,c onsisting of ap henylr ing, either unsubstituted or with fluorine on the meta or para position, did not significantly inhibit SETD7 methyltransferase activity,i ndicating the essential role of the tetrahydroisoquinoline scaffold of (R)-PFI-2i ni nhibitiono fS ETD7. IC 50 values of > 100 mm wereo bserved for severalh eteroatom-substituted analogues 20-22,c ontaining for instanceaplanar or nonplanar heterocyclic system.T oi nvestigate the importance of the fluorine substituent, we synthesized analogue 23,w hich has an IC 50 value of 532 nm;t his is an approximatet wofold increasew ith respectt of luorinecontaining compound 7 (IC 50 = 266 nm). Approximately 10 % inhibition of methyltransferase activity was observed in the presence of 100 mm of compound 24,a na nalogue of 7 that has the positively charged quaternary ammonium group (under physiological conditions) replaced by an eutralm ethylene group of equal size (SI Figure S1 ). Thisr esult demonstrates that the positively charged NH 2 + of (R)-PFI-2 is involvedi nt wo interactions with SETD7, namely as as alt bridge with Asp256 and ah ydrogen bond with His252. Notably,when this nitrogen was translocated one position, as in tetrahydroquinoline 25, again no inhibition was observed, whereas for compound 26, only ap oor inhibition with an IC 50 value of 20 mm was observed. Based on our examination of compounds 23-26,i ti s clearly evident that the most important contributor to the excellent potencyo f( R)-PFI-2 is the nitrogen-containing tetrahydroisoquinoline functionality.H aving ab enzylamine moiety instead of the cyclic structure, as in compound 27,am oderately active compound is obtained (IC 50 = 2.7 mm). With compound 28,aformation of as alt bridgei sn ol onger possible after changing the free amine to an amide functionality,a nd consequently no inhibition was observed. The two individual fragments of which the (R)-PFI-2 scaffold consists also showedn o inhibitory activity (Figure 3 , compounds 29 and 30).
Docking studies were then carriedo ut to obtain more detailed informationa bout the potential binding modes of various (R)-PFI-2 analogues (Figure 4a-f) . Initially,t oc onfirm the correct docking mode, (R)-PFI-2 was successfully redocked into the structure of SETD7 (RMSD = 0.638 ,F igure 4a). The ligand interaction diagramf or SETD7-(R)-PFI-2 is shown in SI Figure S3 . Compound 8 was docked into SETD7 and the binding mode of 8 was found to be similar to that of (R)-PFI-2 (Figure 4b ). In the docked structure of 12,t he piperidine group occupies the narrow lysine binding channel;a lthough it is somewhat larger than (R)-PFI-2'sp yrrolidine group, 12 does not noticeably clash with the protein (Figure 4c ). Finally,t wo structures with the tetrahydroisoquinoline core were docked. Despite being av ery poor inhibitor of SETD7 (10 %i nhibition at 100 mm,S IF igure S1), dockingo ft he carbon analogue 24 was successful and the apparent binding mode seems similar to that of (R)-PFI-2, in spiteo ft he absence of interactions with Asp256 and His252 (Figure 4d ). In contrast, the benzylaminederived compound 27 does have ap otentialt of orm as alt bridge with Asp256 and ah ydrogen bond with His252u nder physiological conditions, and docking of this molecule into SETD7 confirmed the existence of the energetically favorable salt bridge and hydrogen bond (Figure 4e ).
Conclusions
Al ibrary of 29 (R)-PFI-2 analogues was synthesized and evaluated as SETD7 inhibitors with the aim to determine which structuralf eatures contribute to the excellent potency of (R)-PFI-2. Our resultsd emonstrate that small perturbationsi nt he pyrrolidine amide side chain, that is, piperidine amide 12 or dimethylamide 15 were tolerated relativelyw ell, whereas substituents with more rotational freedom (e.g.,d iethylamide 14) Figure 3 . Al ibrary of (R)-PFI-2 (compound 1)a nd its analogues 2-30,s howing half-maximum inhibitory concentrations(IC 50 values). ChemMedChem 2018 ChemMedChem , 13,1405 ChemMedChem -1413 www.chemmedchem.org or with increased size (e.g.,a damantane 10)w ere not tolerated. Substitutions on the aromatics ide chain led to highly potent (R)-PFI-2 analogues. The key interactions between SETD7 and (R)-PFI-2 were identified to be as alt bridge and a hydrogen bond that are formed between SETD7'sAsp256/ His252 and the tetrahydroisoquinoline's NH 2 + group of (R)-PFI-2. Removal or repositioningo ft his ammonium group resulted in analoguest hat were inactive (compounds 24 and 25)o r only poorly active (compound 26), whereas ar eplacement of the tetrahydroisoquinoline moiety by benzylamine (as in compound 27)r esulted in a % 10-foldl ess potent inhibitor.I ti se nvisioned that this study will importantly contributet ot he growingf ield of epigenetic drug discovery.
Experimental Section
Inhibition studies:F or determination of IC 50 values, aM ALDI-TOF-MS-based assay monitoring methylation of a21-mer histone 3pep-tide mimic containing al ysine at position 4w as used. Briefly, SETD7 (200 nm final concentration) was pre-incubated with compound (100 %D MSO stock solution at appropriate concentration) for 5min at 37 8Ci n1 8mLo f5 0mm glycine pH 8.8 containing 2.5 %g lycerol as assay buffer.T hen, 2 mLo fS AM (16 mm final concentration) and 21-mer H3K4 peptide (10 mm final concentration) premixture was added to initiate the enzymatic reaction, thereby obtaining af inal reaction volume of 20 mLc ontaining 5% DMSO (v/v). The reaction was left to incubate for an additional 1h at 37 8Ca fter which it was quenched by the addition of 20 mLo f methanol. For MALDI-TOFM Sa nalysis, a2mLa liquot from the quenched reaction mixture was mixed with 8 mLo fs aturated HCCA matrix (a-cyano-4-hydroxycinnamic acid, Sigma-Aldrich). From this mixture 1 mLw as deposited on the MALDI plate for crystallization. Methyltransferase activity was calculated by taking the peak area of monomethylation state (including all isotopes and adducts), and is expressed relative to the reaction in which no compound was present (control experiment in which just 5% DMSO was present). The calculated activities were plotted against the corresponding compound concentrations and fitted to the Hill equation using OriginPro 2017 SR2 software (version b9.4.2.380). Each experiment was performed in triplicate.
Docking studies:T he crystal structure of SETD7 in complex with (R)-PFI-2 and S-adenosylmethionine (SAM) [24] was downloaded from the RCSB Protein Data Bank (PDB ID:4 JLG). The protein-ligand complex (chain A) was prepared for docking using the QuickPrep wizard in Molecular Operating Environment (MOE).
[26] All compounds to be docked were prepared using the default settings of the Wash wizard as implemented in MOE. Molecular docking was performed using Molegro Virtual Docker v6.0.
[27] The active binding site region was defined as as pherical region, which encompasses all protein within 10.0 of bound (R)-PFI-2. Both the MolDock Score [GRID] and PLANTS Score [GRID] with ag rid resolution of 0.2 were evaluated to score and rank the five best docking poses for each compound. MolDock SE was selected as search algorithm using its default settings. All figures were prepared with PyMOL visualization software. [28] Characterization of final compounds:C ompound 1 (25 mg, 75 % isolated yield, off-white solid): 1 168.4, 159.7, 157.8, 138.9, 138.9, 138.7, 138.6, 138.0, 132.3, 130.2,  130.0, 128.8, 128.3, 128.2, 128.2, 123.3, 123.3, 122.4, 111.0, 110.8,  55.9, 46.2, 45.9, 42.7, 42.2, 42.2, 39.8, 39.7, 29.7, 29.3, 28.7, 25.8 30 (m, 1H), 1.60-1.50 (m, 3H), 1.47-1.40 ppm (m, 1H) ;
